Protein Hydrolyzation and Glycemic Control

This study has been completed.
Sponsor:
Information provided by:
Maastricht University Medical Center
ClinicalTrials.gov Identifier:
NCT01034618
First received: December 16, 2009
Last updated: NA
Last verified: December 2009
History: No changes posted

December 16, 2009
December 16, 2009
December 2007
October 2008   (final data collection date for primary outcome measure)
Glucose and insulin homeostasis. [ Designated as safety issue: No ]
Same as current
No Changes Posted
Plasma amino acid profiles [ Designated as safety issue: No ]
Same as current
Not Provided
Not Provided
 
Protein Hydrolyzation and Glycemic Control
The Additional Effects of Protein Hydrolysate Supplementation on Glucose Homeostasis in Type 2 Diabetes

The insulinotropic effects of protein hydrolysate/amino acid ingestion have been shown to regulate blood glucose homeostasis in both type 2 diabetes patients and normoglycemic controls. The objective of the study is to investigate the optimal dose of such an insulinotropic mixture.

Not Provided
Interventional
Not Provided
Intervention Model: Crossover Assignment
Masking: Double Blind (Subject, Investigator)
Primary Purpose: Basic Science
Diabetes
Dietary Supplement: Protein hydrolyzation
  • Placebo Comparator: Placebo
    Intervention: Dietary Supplement: Protein hydrolyzation
  • Experimental: Intact protein
    Intervention: Dietary Supplement: Protein hydrolyzation
  • Experimental: Protein hydrolysate
    Intervention: Dietary Supplement: Protein hydrolyzation
Not Provided

*   Includes publications given by the data provider as well as publications identified by ClinicalTrials.gov Identifier (NCT Number) in Medline.
 
Completed
Not Provided
April 2009
October 2008   (final data collection date for primary outcome measure)

Inclusion Criteria:

  • Male
  • Age between 40 and 70 years
  • Oral blood glucose lowering medication
  • BMI < 35 kg/m2

Exclusion Criteria:

  • Exogenous insulin use
  • Cardiac disease (any cardiac event in the last 5 years)
  • Diabetic complications (microvascular complications, microalbuminuria: albumin:creatinine ratio >2,5)
Male
40 Years to 70 Years
No
Contact information is only displayed when the study is recruiting subjects
Netherlands
 
NCT01034618
06-3-081
No
Ralph J.F. Manders, PhD, Maastricht University Medical Center
Maastricht University Medical Center
Not Provided
Not Provided
Maastricht University Medical Center
December 2009

ICMJE     Data element required by the International Committee of Medical Journal Editors and the World Health Organization ICTRP